Physician profile
Robert W Buster
NPI 1841343076
$8,117.14
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,311 · 2020: $1,085 · 2021: $1,013 · 2022: $708.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,592.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,233.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $604.24 | 2019-2022 | |
| Amarin Pharma, INC. | $575.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $479.82 | 2019-2020 | |
| Glaxosmithkline, LLC. | $396.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $351.69 | 2019-2020 | |
| Pfizer INC. | $292.45 | 2019-2020 | |
| Sanofi Pasteur INC. | $259.84 | 2019-2020 | |
| Novo Nordisk INC | $237.55 | 2019-2020 | |
| Lilly USA, LLC | $170.04 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $148.50 | 2021 | |
| Insmed, INC. | $146.40 | 2019-2020 | |
| Allergan, INC. | $145.09 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $144.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.51 | 2022 | |
| Merck Sharp & Dohme LLC | $116.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $98.76 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $72.48 | 2019-2020 | |
| Shire North American Group INC | $66.70 | 2019 | |
| Abbvie INC. | $52.85 | 2019-2021 | |
| Aytu Biopharma, INC. | $52.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.03 | 2019 | |
| Astellas Pharma US INC | $46.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $42.29 | 2019 | |
| Advanced Respiratory, INC | $35.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.20 | 2019 | |
| Radius Health, INC. | $28.75 | 2019 | |
| Circassia INC. | $24.67 | 2019 | |
| Phadia US INC. | $18.74 | 2020 | |
| Antares Pharma, INC. | $15.61 | 2019 | |
| Mylan Specialty L.P. | $13.47 | 2019 | |
| Mayne Pharma Commercial LLC | $11.71 | 2019 | |
| Genentech USA, INC. | $11.06 | 2019 | |
| Medicure Pharma INC. | $10.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Buster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.